The NIH, at a time of deep uncertainty, is losing its longtime No. 2 official, Larry Tabak, to retirement, STAT has learned.

Potential delays in clinical trials may result in extended timelines for new drug approvals, and a sudden reduction in ...

Pacific Biosciences of California, Inc. ( NASDAQ: PACB) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Todd Friedman - Senior Director, Finance and Investor Relations Christian Henry - ...

Nashville-born, North Carolina-bred Dr. James Crowe, Jr. was a curious kid. His appetite for reading was insatiable-which was evident in his weekly ...

New research suggests that Alzheimer’s disease damages the brain in two separate phases, with the first phase happening ...

The No. 2 in command at the National Institutes of Health, Dr. Lawrence A. Tabak, who served as acting director of the agency ...

Two key staff members at the National Institutes of Health (NIH) are reportedly leaving the agency amid ongoing efforts by ...

The National Institute of Health's principal deputy director, Dr. Lawrence A. Tabak, resigned and retired from government ...

The 15% cap is necessary to “ensure that as many funds as possible go towards direct scientific research costs rather than administrative overhead”, acting NIH director Matthew Memoli said in ...

A coalition of attorneys general from 22 states announced Monday they are suing the Trump administration to stop steep cuts to how medical research grants are funded by the National Institutes of ...

The National Institutes of Health (NIH) on Friday made a significant reduction in grants reserved for research institutions, a decision that may significantly impact American higher education.

The NIH, the nation’s top funder of biomedical ... and grinding research to a halt — soon,” said Robert Winn, the director of the Massey Comprehensive Cancer Center at Virginia Commonwealth ...